Las Vegas—The opioid-induced constipation drug naldemedine was shown to be safer and more effective than placebo in patients with chronic noncancer pain taking opioids across a range of doses, according to the pooled results of two clinical trials.
Pooled data for spontaneous bowel movements (SBMs) and overall treatment-emergent adverse events (TEAEs) from the 12-week COMPOSE-1 and COMPOSE-2 studies were analyzed for patients with chronic pain experiencing opioid-induced constipation (OIC)